CCND1基因与弥漫大B细胞淋巴瘤关系的研究进展
|
摘要
CCND1基因在乳腺癌、肺癌、肝癌和头颈部肿瘤等实体肿瘤中都有表达,其编码产物Cyclin D1是调控细胞周期G1期的关键蛋白,促进细胞周期由G1期进入S期,其基因多态性和肿瘤的易感性密切相关,因此在肿瘤的发生发展中起着重要的作用。近期国内外的研究发现,Cyclin D1在弥漫大B细胞淋巴瘤(DLBCL)也有表达,并且有一定的生物学意义,与DLBCL的发生部位、是否表达CD5及预后等均有相关性。但对于Cyclin D1的检测率各家报道不相一致,同时CCND1基因的检测结果更低。本文就CCND1基因及其编码产物Cyclin D1在DLBCL中的表达和临床意义作一综述。
CCND1 gene express in many solid tumor such as breast cancer, lung cancer, hepatic carcinoma, head and neck neoplasm. The coding product of this gene is Cyclin D1 protein,which is a kind of critical protein in regulating G1 of cell cycle, promoting the cell cycle from G1 phase to S phase. CCND1 gene polymorphism is closely related to tumor susceptibility, therefore it plays an important role in the occurrence and development of tumor. Recent studies at home and abroad have found that Cyclin D1 is also expressed in diffuse large B-cell lymphoma(DLBCL), and has certain biological significance, which is related to the location of DLBCL, whether CD5 is expressed or not and prognosis. However, the detection rate of Cyclin D1 was not consistent with the reports of other countries, and the detection rate of CCND1 gene was lower. This article reviews the expression and clinical significance of CCND1 gene and its coding product Cyclin D1 in DLBCL.
CCND1 gene express in many solid tumor such as breast cancer, lung cancer, hepatic carcinoma, head and neck neoplasm. The coding product of this gene is Cyclin D1 protein,which is a kind of critical protein in regulating G1 of cell cycle, promoting the cell cycle from G1 phase to S phase. CCND1 gene polymorphism is closely related to tumor susceptibility, therefore it plays an important role in the occurrence and development of tumor. Recent studies at home and abroad have found that Cyclin D1 is also expressed in diffuse large B-cell lymphoma(DLBCL), and has certain biological significance, which is related to the location of DLBCL, whether CD5 is expressed or not and prognosis. However, the detection rate of Cyclin D1 was not consistent with the reports of other countries, and the detection rate of CCND1 gene was lower. This article reviews the expression and clinical significance of CCND1 gene and its coding product Cyclin D1 in DLBCL.
引文
[1] MOTOKURA T,BLOOM T,KIM H G,et al.A novel cyclin encoded by a bcl1-linked candidate oncogene[J].Nature,1991,350(6318):512.
[2] CHYTIL A,WALTNER-LAW M,WEST R,et al.Construction of a cyclin D1-Cdk2 fusion protein to model the biological functions of cyclin D1-Cdk2 complexes[J].J Biol Chem,2004,279(46):47688-47698.
[3] ZHANG YJ,JIANG W,CHEN CJ,et al.Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma[J].Biochem Biophys Res Commun,1993,196(2):1010-1016.
[4] KEYOMARSI K, PARDEE AB.Redundant cyclin overexpression and gene amplification in breast cancer cells[J].Proc Natl Acad Sci,1993,90(3):1112-1116.
[5] ZHOU JX,NIEHANS GA,SHAR A,et al.Mechanisms of G1 checkpoint loss in resected early stage non-small cell lung cancer[J].Lung Cancer,2001,32(1):27-38.
[6]董吉顺,倪灿荣.胃癌中survivin、PTEN、cyclinD1和p53基因的表达及其相关性[J].临床与实验病理学杂志,2003,19(4):396-400.
[7] ARBER N,GAMMON MD,HIBSHOOSH H,et al.Overexpression of cyclin D1 occurs in both squamous carcinomas and adenocarcinomas of the esophagus and in adenocarcinomas of the stomach[J].Hum Pathol,1999,30(9):1087-1092.
[8] WORSLEY SD,PONDER BA,DAVIES BR.Overexpression of cyclin D1in epithelial ovarian cancers[J].Gynecol Oncol,1997,64(2):189-195.
[9] LI X,GAO Z,ZHOUX,et al.The relative frequencies of lymphoma subtypes in China-a nationwide study of 10 002 cases by the Chinese Lymphoma Study Group(CLSG)[J].Ann Oncol,2011,22(Suppl 4):141-146.
[10]中华医学会血液学分会,中国抗癌协会淋巴瘤专业委员会.中国弥漫大B细胞淋巴瘤诊断与治疗指南(2013年版)[J].中华血液学杂志,2013,34(9):816-819.
[11] HU S,XU-MONETTE ZY,TZANKOV A,et al.MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates highrisk gene expression signatures:a report from the international DLBCL rituximab-CHOP consortium Program[J].Blood,2013,121(20):4021-4031.
[12]俞文娟,曹利红,王敬瀚,等.弥漫大B细胞淋巴瘤患者蛋白表达检测的预后意义[J].中华血液学杂志,2017,38(9):784-788.
[13] BRIZOVA H,KALINOVA M,KRSKOVA L,et al.Quantitative monitoring of cyclin D1 expression:a molecular marker for minimal residual disease monitoring and a predictor of the disease outcome in patients with mantle cell lymphoma[J].Int J Cancer,2008,123(12):2865-2870.
[14] PENG W,WU J,FENG J.LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy[J].Clin Exp Med,2017,17(1):1-8.
[15] WO NIALIS N,GIEREJ B,POPLAWSKA L,et al.A rare CD5-positive subgroup of diffuse large B-cell lymphoma–clinical,morphological and immunophenotypic features in Polish patients[J].Pol J Pathol,2016,67(3):235-243.
[16] ZUKERBERG LR,YANG WI,ARNOLD A,et al.Cyclin D1 expression in non-Hodgkin's lymphomas. Detection by immunohistochemistry[J].Am J Clin Pathol,1995,103(6):756-60.
[17] BAI M,TSANOU E,AGNANTIS NJ,et al.Expression of cyclin D3 and cyclin E and identification of distinct clusters of proliferation and apoptosis in diffuse large B-cell lymphomas[J].Histol Histopathol,2003,18(2):449-457.
[18] RODRIGUEZ-JUSTO M,HUANG Y,YE H,et al.Cyclin D1-positive diffuse large B-cell lymphoma[J].Histopathol,2008,62(7):900-903.
[19] CHEN BJ,RUMINY P,ROTH CG,et al.Cyclin D1-positive Mediastinal Large B-Cell Lymphoma With Copy Number Gains of CCND1 Gene[J].Am J Surg Pathol,2019,43(1):110-120.
[20] RAM N,RASHID O,FAROOQ S,et al.Primary adrenal non-Hodgkin lymphoma:a case report and review of the literature[J].J Med Case Rep,2017,11(1):108.
[21] MALIPATEL R,PATIL M,ROUT PP,et al.Primary gastric lymphoma:clinicopathological profile[J].Euroasian J Hepatogastroenterol,2018,8(1):6-10.
[22] VELA-CH魣VEZ T,ADAM P,KREMER M,et al.Cyclin D1 positive diffuse large B-cell lymphoma is a post-germinal center-type lymphoma without alterations in the CCND1 gene locus[J].Leuk Lymphoma,2011,52(3):458-466.
[23] HSIAO SC,CORTADA IR,COLOMO L,et al.SOX11 is useful in differentiating cyclin D1-positive diffuse large B-cell lymphoma from mantle cell lymphoma[J].Histopathol,2012,61(4):685-693.
[24] TERUYA-FELDSTEIN J,GOPALAN A,MOSKOWITZ CH.CD5 Negative, Cyclin D1-positive Diffuse Large B-cell Lymphoma(DL BCL)Presenting as Ruptured Spleen[J].App Immunohistochem Mol Morphol,2009,17(3):255-258.
[25] YAMAGUCHI M,SETO M,OKAMOTO M,et al.De novo CD5+diffuse large B-cell lymphoma:a clinicopathologic study of 109 patients[J].Blood,2002,99(3):815-821.
[26] LIANG X,WANG J,BAI W,et al.Expression of CD68, cyclin D1 and rearrangement of bcl-6 gene are adverse prognostic factors in diffuse large B-cell lymphoma[J].Zhonghua Bing Li Xue Za Zhi,2015,44(8):559-564.
[27]梁晓杰,王晋芬,白纬,等.CD68、cyclin D 1蛋白和bcl-6基因在弥漫性大B细胞淋巴瘤中的表达及意义[J].中华病理学杂志,2015,44(8):559-564.
[28] OK CY,XU-MONETTE ZY,TZANKOV A,et al.Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma(DLBCL)treated with immunochemotherapy:a report from the International DLBCL Rituximab-CHOP Consortium Program[J].Cancer,120(12):1818-1829.
[29]杨晶晶,闫志凌,徐开林.套细胞淋巴瘤中SOX11差异性表达的研究进展[J].白血病·淋巴瘤,2018,27(5):308-311.
[30]许小宇,桑威.CARMA1基因在活化B细胞样亚型弥漫大B细胞淋巴瘤中的研究进展[J].国际输血及血液学杂志,2015,38(2):157-161.
[31]鲍丽丽.C-MYC基因在弥漫性大B细胞淋巴瘤中的研究进展[J].国际输血及血液学杂志,2015,38(5):436-440.
[32]张宏伟,程牛亮.弥漫性大B细胞淋巴瘤t(14;18)易位和c-myc基因重排研究进展[J].白血病·淋巴瘤,2009,18(10):630-633.
[2] CHYTIL A,WALTNER-LAW M,WEST R,et al.Construction of a cyclin D1-Cdk2 fusion protein to model the biological functions of cyclin D1-Cdk2 complexes[J].J Biol Chem,2004,279(46):47688-47698.
[3] ZHANG YJ,JIANG W,CHEN CJ,et al.Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma[J].Biochem Biophys Res Commun,1993,196(2):1010-1016.
[4] KEYOMARSI K, PARDEE AB.Redundant cyclin overexpression and gene amplification in breast cancer cells[J].Proc Natl Acad Sci,1993,90(3):1112-1116.
[5] ZHOU JX,NIEHANS GA,SHAR A,et al.Mechanisms of G1 checkpoint loss in resected early stage non-small cell lung cancer[J].Lung Cancer,2001,32(1):27-38.
[6]董吉顺,倪灿荣.胃癌中survivin、PTEN、cyclinD1和p53基因的表达及其相关性[J].临床与实验病理学杂志,2003,19(4):396-400.
[7] ARBER N,GAMMON MD,HIBSHOOSH H,et al.Overexpression of cyclin D1 occurs in both squamous carcinomas and adenocarcinomas of the esophagus and in adenocarcinomas of the stomach[J].Hum Pathol,1999,30(9):1087-1092.
[8] WORSLEY SD,PONDER BA,DAVIES BR.Overexpression of cyclin D1in epithelial ovarian cancers[J].Gynecol Oncol,1997,64(2):189-195.
[9] LI X,GAO Z,ZHOUX,et al.The relative frequencies of lymphoma subtypes in China-a nationwide study of 10 002 cases by the Chinese Lymphoma Study Group(CLSG)[J].Ann Oncol,2011,22(Suppl 4):141-146.
[10]中华医学会血液学分会,中国抗癌协会淋巴瘤专业委员会.中国弥漫大B细胞淋巴瘤诊断与治疗指南(2013年版)[J].中华血液学杂志,2013,34(9):816-819.
[11] HU S,XU-MONETTE ZY,TZANKOV A,et al.MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates highrisk gene expression signatures:a report from the international DLBCL rituximab-CHOP consortium Program[J].Blood,2013,121(20):4021-4031.
[12]俞文娟,曹利红,王敬瀚,等.弥漫大B细胞淋巴瘤患者蛋白表达检测的预后意义[J].中华血液学杂志,2017,38(9):784-788.
[13] BRIZOVA H,KALINOVA M,KRSKOVA L,et al.Quantitative monitoring of cyclin D1 expression:a molecular marker for minimal residual disease monitoring and a predictor of the disease outcome in patients with mantle cell lymphoma[J].Int J Cancer,2008,123(12):2865-2870.
[14] PENG W,WU J,FENG J.LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy[J].Clin Exp Med,2017,17(1):1-8.
[15] WO NIALIS N,GIEREJ B,POPLAWSKA L,et al.A rare CD5-positive subgroup of diffuse large B-cell lymphoma–clinical,morphological and immunophenotypic features in Polish patients[J].Pol J Pathol,2016,67(3):235-243.
[16] ZUKERBERG LR,YANG WI,ARNOLD A,et al.Cyclin D1 expression in non-Hodgkin's lymphomas. Detection by immunohistochemistry[J].Am J Clin Pathol,1995,103(6):756-60.
[17] BAI M,TSANOU E,AGNANTIS NJ,et al.Expression of cyclin D3 and cyclin E and identification of distinct clusters of proliferation and apoptosis in diffuse large B-cell lymphomas[J].Histol Histopathol,2003,18(2):449-457.
[18] RODRIGUEZ-JUSTO M,HUANG Y,YE H,et al.Cyclin D1-positive diffuse large B-cell lymphoma[J].Histopathol,2008,62(7):900-903.
[19] CHEN BJ,RUMINY P,ROTH CG,et al.Cyclin D1-positive Mediastinal Large B-Cell Lymphoma With Copy Number Gains of CCND1 Gene[J].Am J Surg Pathol,2019,43(1):110-120.
[20] RAM N,RASHID O,FAROOQ S,et al.Primary adrenal non-Hodgkin lymphoma:a case report and review of the literature[J].J Med Case Rep,2017,11(1):108.
[21] MALIPATEL R,PATIL M,ROUT PP,et al.Primary gastric lymphoma:clinicopathological profile[J].Euroasian J Hepatogastroenterol,2018,8(1):6-10.
[22] VELA-CH魣VEZ T,ADAM P,KREMER M,et al.Cyclin D1 positive diffuse large B-cell lymphoma is a post-germinal center-type lymphoma without alterations in the CCND1 gene locus[J].Leuk Lymphoma,2011,52(3):458-466.
[23] HSIAO SC,CORTADA IR,COLOMO L,et al.SOX11 is useful in differentiating cyclin D1-positive diffuse large B-cell lymphoma from mantle cell lymphoma[J].Histopathol,2012,61(4):685-693.
[24] TERUYA-FELDSTEIN J,GOPALAN A,MOSKOWITZ CH.CD5 Negative, Cyclin D1-positive Diffuse Large B-cell Lymphoma(DL BCL)Presenting as Ruptured Spleen[J].App Immunohistochem Mol Morphol,2009,17(3):255-258.
[25] YAMAGUCHI M,SETO M,OKAMOTO M,et al.De novo CD5+diffuse large B-cell lymphoma:a clinicopathologic study of 109 patients[J].Blood,2002,99(3):815-821.
[26] LIANG X,WANG J,BAI W,et al.Expression of CD68, cyclin D1 and rearrangement of bcl-6 gene are adverse prognostic factors in diffuse large B-cell lymphoma[J].Zhonghua Bing Li Xue Za Zhi,2015,44(8):559-564.
[27]梁晓杰,王晋芬,白纬,等.CD68、cyclin D 1蛋白和bcl-6基因在弥漫性大B细胞淋巴瘤中的表达及意义[J].中华病理学杂志,2015,44(8):559-564.
[28] OK CY,XU-MONETTE ZY,TZANKOV A,et al.Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma(DLBCL)treated with immunochemotherapy:a report from the International DLBCL Rituximab-CHOP Consortium Program[J].Cancer,120(12):1818-1829.
[29]杨晶晶,闫志凌,徐开林.套细胞淋巴瘤中SOX11差异性表达的研究进展[J].白血病·淋巴瘤,2018,27(5):308-311.
[30]许小宇,桑威.CARMA1基因在活化B细胞样亚型弥漫大B细胞淋巴瘤中的研究进展[J].国际输血及血液学杂志,2015,38(2):157-161.
[31]鲍丽丽.C-MYC基因在弥漫性大B细胞淋巴瘤中的研究进展[J].国际输血及血液学杂志,2015,38(5):436-440.
[32]张宏伟,程牛亮.弥漫性大B细胞淋巴瘤t(14;18)易位和c-myc基因重排研究进展[J].白血病·淋巴瘤,2009,18(10):630-633.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |